Extracorporeal photopheresis for graft-versus-host disease: The role of patient, transplant, and classification criteria and hematologic values on outcome - Results from a large single-center study

Transfusion

Volumn 55, Issue 4, 2015, Pages 736-747

  Berger, Massimo ^a   Albiani, Roberto ^a   Sini, Bruno ^a   Fagioli, Franca ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PUVA; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; BLOOD; BLOOD GROUP INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOTOPHERESIS; PRESCHOOL CHILD; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BIOMARKERS; BLOOD GROUP INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOTOPHERESIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84926482953     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12900     Document Type: Article

References (48)

1. Jaglowski SM, Devine SM,. Graft-versus-host disease: why have we not made more progress? Curr Opin Hematol 2014; 21: 141-147.
2. Lorenz E, Uphoff D, Reid TR, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12: 197-201.
3. Billingham RE,. The biology of graft-versus-host reactions. Harvey Lect 1966-67;62:21-78.
4. van Bekkum DW, de Vries MJ,. Radiation chimeras. New York: Academic Press; 1967.
5. Martin PJ, Rizzo JD, Wingard JR, et al. First and second-line systemic treatment of acute graft-versus-host disease. Recommendation of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-1163.
6. Ferrara JL, Deeg HJ,. Graft-versus-host disease. N Engl J Med 1991; 325: 357-358.
7. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
8. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving antithymocyte globulin. Blood 2006; 107: 4177-4181.
9. Atkinson K,. Chronic graft versus host disease. Bone Marrow Transplant 1990; 5: 69-82.
10. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 1988; 72: 555-561.
11. Vogelsang GB,. How I treat chronic graft versus host disease. Blood 2001; 97: 1196-1201.
12. Locatelli F, Uderzo C, Dini G, et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627-633.
13. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
14. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
15. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38-45.
16. Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) after unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant 2007; 13: 1145-1152.
17. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
18. Martin PJ, Storer BE, Carpenter PA, et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 124-132.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
20. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
21. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 117: 6714-6720.
22. Vigorito AC, Campregher PV, Storer BE, et al.; National Institutes of Health. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-708.
23. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748-758.
24. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28: 145-284.
25. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515-1521.
26. Kuzmina Z, Greinix HT, Knobler R, et al. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood 2009; 114: 744-746.
27. Berger C, Hoffmann K, Vasquez JG, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010; 116: 4838-4847.
28. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127.
29. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
30. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
31. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409-417.
32. Kim HT,. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-565.
33. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
34. Bland JM, Altman DG,. The log rank test. BMJ 2004; 328: 1073.
35. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
36. Koreth J, Antin JH,. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 2008; 1: 111.
37. Marshall SR,. Technology insight: ECP for the treatment of GVHD-can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3: 302-314.
38. Holler E,. Risk assessment in haematopoietic stem cell transplantation: GVHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281-294.
39. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968-5976.
40. Gerner M, Hölig K, Wehner R, et al. Extracorporeal photopheresis efficiently impairs the proinflammatory capacity of human 6-sulfo LacNAc dendritic cells. Transplantation 2009; 87: 1134-1139.
41. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-39.
42. Di Renzo M, Rubegni P, Pasqui AL, et al. Extracorporeal photopheresis affects interleukin (IL)-10 and IL-12 production by monocytes in patients with chronic graft-versus-host disease. Br J Dermatol 2005; 153: 59-65.
43. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
44. Spisek R, Gasova Z, Bartunkova J,. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion 2006; 46: 55-65.
45. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010; 50: 1359-1369.
46. Greinix HT, Worel N, Knobler R,. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 1747-1751.
47. Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008; 42: 421-425.
48. Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 2007; 29: 678-687.